Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse Multiple Myeloma”

1,566 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,566 results

Testing effectiveness (Phase 2)WithdrawnNCT05170789
What this trial is testing

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Tulane University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Who this might be right for
Multiple Myeloma
Cephalon 62
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Large-scale testing (Phase 3)Study completedNCT00546780
What this trial is testing

Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 31
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Not applicableNot Yet RecruitingNCT06472479
What this trial is testing

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University 66
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Large-scale testing (Phase 3)Study completedNCT00657488
What this trial is testing

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 400
Post-approval studies (Phase 4)Not Yet RecruitingNCT07191379
What this trial is testing

Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Odense University Hospital 50
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Early research (Phase 1)Study completedNCT04671251
What this trial is testing

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Avalo Therapeutics, Inc. 13
Testing effectiveness (Phase 2)Ended earlyNCT00765102
What this trial is testing

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 32
Testing effectiveness (Phase 2)Looking for participantsNCT05594797
What this trial is testing

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT02988466
What this trial is testing

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Who this might be right for
Hematologic Malignancies
Masonic Cancer Center, University of Minnesota 78
Early research (Phase 1)WithdrawnNCT06411301
What this trial is testing

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Who this might be right for
Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression
Jules Bordet Institute
Very early researchUnknownNCT04156269
What this trial is testing

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT00891137
What this trial is testing

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma+2 more
Cellerant Therapeutics 30
Load More Results